Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 3/20 | 0.45 |
| ▸ | MTTP | P55157 | 3/20 | 0.45 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 6/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | USP8 | P40818 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502663 | 0.95 | APOB (0.44) | APOBMTTPSREBF2P2RY14POLB | |
| SCHEMBL6496973 | 0.94 | SREBF2 (0.41) | APOBMTTPSREBF2MAPTKDM4E | |
| SCHEMBL6489597 | 0.91 | MAPT (0.40) | SREBF2MAPTKDM4ELMNA | |
| SCHEMBL6491198 | 0.90 | APOB (0.39) | APOBMTTPSREBF2P2RY14POLB | |
| SCHEMBL6491615 | 0.89 | SREBF2 (0.39) | APOBMTTPSREBF2MAPTKDM4E | |
| SCHEMBL6499741 | 0.89 | SREBF2 (0.40) | SREBF2MAPTSIRT5 | |
| SCHEMBL6491047 | 0.88 | APOB (0.44) | APOBMTTPPOLBMAPTKDM4E | |
| SCHEMBL6794499 | 0.87 | CYP3A4 (0.40) | MTTPSREBF2POLBMAPTKDM4E | |
| SCHEMBL6499352 | 0.86 | MAPT (0.39) | SREBF2MAPTKDM4ELMNA | |
| SCHEMBL6491334 | 0.86 | GCGR (0.43) | SREBF2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | APOB 1/4885MTTP 677/4885SREBF2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.